亚虹医药：国家药品监督管理局药品审评中心已完成APL-1702的技术评审

Core Viewpoint - Yahui Pharmaceutical has completed the technical review of APL-1702 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration and is accelerating the approval process for its market launch [1] Group 1 - The company aims to obtain market approval for APL-1702 as soon as possible [1] - The company will strictly adhere to the information disclosure obligations as per the Shanghai Stock Exchange's Sci-Tech Innovation Board listing rules and other relevant regulations [1]